Any current/future new fundraising through debt or equity?

No explicit mention of any current or planned fundraising through debt or equity was made in the provided transcript. The focus appears to be on organic and inorganic growth through expansion of centers and possible acquisitions, financed through internal resources. CAPEX guidance for FY '26 is around Rs. 70 crore, with no indication of requiring external fundraising. The management indicated they are "too new to the process" regarding dividends and seem focused on stabilizing operations and understanding the public market before considering such moves. No direct references to raising new fund

Any current/future capex/capital investment/strategic investment?

Planned CAPEX for FY '26 is around Rs. 70 crore (Ritu Mittal). CAPEX mainly for opening new centers: 4 big centers (~Rs. 10 Cr each) and 4 small centers (Rs. 1.5-2 Cr each). Additional CAPEX may depend on PPP centers, but exact numbers unknown due to tender-based process. Strategic investment includes establishment of MRI at Calcutta Medical College within 90 days. Investment to build genomic lab, expected to launch soon, enhancing B2B business. Focus on expanding the network with 15-18 new centers planned in FY '26. Potential acquisitions in Eastern India considered if they fit quality and pr

Future growth expectations in sales/revenue/volumes?

Expected revenue growth for FY '26 is around 18%-20% compared to FY '25. Volume of tests conducted has been growing at around 10% year-on-year between FY '24 and FY '25. Price increases are planned at around 2%-3% every alternate year. Market share impact from new competitors entering Eastern India has not been seen yet. Opening 15-18 new centers in FY '26, including 8 centers in the first quarter itself, supports growth. Expansion plans focused on Eastern India with potential acquisitions if suitable. Growth also driven by new services such as genomic and fetal medicine tests, exp

Future growth expectations in earnings/operating earnings/profits/EPS?

Expecting revenue growth of 18%-20% in FY '26 compared to FY '25. Anticipated EBITDA margin around 36% for FY '26, up from 34% in FY '25. Continued margin expansion despite new centers opening due to improved operating leverage and mature centers absorbing fixed costs. Profit After Tax (PAT) showed strong 34% growth in FY '25; further growth expected with scaling operations. Business model's strong B2C focus (>93% revenue) supports sustainable margins. Ongoing addition of 15-18 centers planned in FY '26 to drive volume and profitability. CAPEX planned at around Rs. 70 Cr for FY '26 for expansi

Current/ Expected Orderbook/ Pending Orders?

The company does not provide a specific order book or pending orders figure for PPP (Public-Private Partnership) centers as these are awarded through a tendering process and are uncertain. They are in the process of establishing an MRI center in Calcutta Medical College within the next 90 days, noted as a significant opportunity. For the fiscal year 2026, Suraksha plans to add approximately 15-18 new centers. In the first quarter of FY '26, they have already opened 5 centers and plan to open 3 more shortly, totaling 8 centers. The company has secured necessary approvals for the majority of pro

IN US

Sale is live|00:00:00left today

Suraksha Diagnostic LtdQ1 FY25Healthcare Services

Suraksha Diagnostic Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹274P/E: 47.8Market Cap: ₹1.6K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Expected revenue growth for FY '26 is around 18%-20% compared to FY '25.
→Volume of tests conducted has been growing at around 10% year-on-year between FY '24 and FY '25.
→Price increases are planned at around 2%-3% every alternate year.
→Market share impact from new competitors entering Eastern India has not been seen yet.
→Opening 15-18 new centers in FY '26, including 8 centers in the first quarter itself, supports growth.
→Expansion plans focused on Eastern India with potential acquisitions if suitable.
→Growth also driven by new services such as genomic and fetal medicine tests, expected to scale over 2-3 years.
→Mature centers expected to deliver margin expansion due to operating leverage, supporting profitable growth.

Margin guidance

Category 2

→Expecting revenue growth of 18%-20% in FY '26 compared to FY '25.
→Anticipated EBITDA margin around 36% for FY '26, up from 34% in FY '25.
→Continued margin expansion despite new centers opening due to improved operating leverage and mature centers absorbing fixed costs.
→Profit After Tax (PAT) showed strong 34% growth in FY '25; further growth expected with scaling operations.
→Business model's strong B2C focus (>93% revenue) supports sustainable margins.
→Ongoing addition of 15-18 centers planned in FY '26 to drive volume and profitability.
→CAPEX planned at around Rs. 70 Cr for FY '26 for expansion and enhancements.
→New service lines like genomic labs and fetal medicine expected to add growth and diversify revenue.
→Management confident of better financial performance and improved results over next 1-2 years.

3 more insights locked — sign up free to unlock

Fundraise plans

→No explicit mention of any current or planned fundraising through debt or equity was made in the provided transcript.
→The focus appears to be on organic and inorganic growth through expansion of centers and possible acquisitions, financed through internal resources.
→CAPEX guidance for FY '26 is around Rs. 70 crore, with no indication of requiring external fundraising.
→The management indicated they are "too new to the process" regarding dividends and seem focused on stabilizing operations and understanding the public market before considering such moves.
→No direct references to raising new funds via IPOs or debt issuance were made during the Q&A or closing remarks.

Order book

→The company does not provide a specific order book or pending orders figure for PPP (Public-Private Partnership) centers as these are awarded through a tendering process and are uncertain.
→They are in the process of establishing an MRI center in Calcutta Medical College within the next 90 days, noted as a significant opportunity.
→For the fiscal year 2026, Suraksha plans to add approximately 15-18 new centers.
→In the first quarter of FY '26, they have already opened 5 centers and plan to open 3 more shortly, totaling 8 centers.
→The company has secured necessary approvals for the majority of proposed centers, indicating a robust pipeline for center openings.
→They continue to focus on organic growth primarily in Eastern India with potential for acquisitions if suitable.

Capex plans

Yes

→Planned CAPEX for FY '26 is around Rs. 70 crore (Ritu Mittal).
→CAPEX mainly for opening new centers: 4 big centers (~Rs. 10 Cr each) and 4 small centers (Rs. 1.5-2 Cr each).
→Additional CAPEX may depend on PPP centers, but exact numbers unknown due to tender-based process.
→Strategic investment includes establishment of MRI at Calcutta Medical College within 90 days.
→Investment to build genomic lab, expected to launch soon, enhancing B2B business.
→Focus on expanding the network with 15-18 new centers planned in FY '26.
→Potential acquisitions in Eastern India considered if they fit quality and price criteria.
→Emphasis on technology enhancement and operational efficiency as part of future growth.

How does Suraksha Diagnostic Ltd rank vs peers in Healthcare Services?

Pro feature

1Suraksha Diagnostic Ltd

Rev 3Mar 2

See full Healthcare Services sector rankings

Want more stocks like Suraksha Diagnostic Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio